Shots:
The EC has approved Boey (trenibotulinumtoxinE) to improve the appearance of mod. to sev. glabellar lines in adults temporarily across all 30 EEA countries
Boey is Europe’s first and only rapid-onset, short-duration botulinum neurotoxin type E, with effects starting in as little as 8 hours and lasting 2–3 weeks.
Boey also received Health Canada approval…
Shots:
The CHMP has recommended Boey (trenibotulinumtoxinE) to improve the appearance of mod. to sev. glabellar lines in adults temporarily; decision is expected in the coming mos., & would apply across all 30 EEA states
Opinion was supported by data from 2 P-III trials assessing the efficacy & safety of Boey in adults with…
Shots:
The US FDA has received BLA for TrenibotE (botulinum neurotoxin serotype E) for the treatment of mod. to sev. glabellar lines
BLA was supported by 2 pivotal P-III (M21-500 & M21-508) trials & an open-label P-III (M21-509) safety study assessing TrenibotE in over 2,100 pts
Trials met their 1 & 2EPs, with onset of…
Shots:
PharmaShots has compiled a list of US FDA-approved drugs in the month of February 2024
The US FDA approved a total of 7 drugs including 6 new molecular entities and 1 biologic leading to the treatments for patients and advances in the healthcare industry
The major highlighted drug was Takeda’s Eohilia (budesonide oral suspension) for treating eosinophilic…
Shots:
The US FDA has granted approval to the company’s Letybo for 50 and 100 units to treat moderate-to-severe glabellar lines in adults
The approval was based on the data from three P-III completed studies that recruited more than 1,000 participants across the US and the EU
The data from the clinical studies showed the…

